PainReform (NASDAQ:PRFX) Stock Price Up 0.4% – Here’s What Happened

PainReform Ltd. (NASDAQ:PRFX)’s stock price rose 0.4% during mid-day trading on Wednesday . The company traded as high as $0.7698 and last traded at $0.7359. Approximately 140,746 shares were traded during trading, a decline of 97% from the average daily volume of 4,605,139 shares. The stock had previously closed at $0.7330.

Analysts Set New Price Targets

PRFX has been the subject of several analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of PainReform in a research note on Thursday, January 22nd. Wall Street Zen upgraded shares of PainReform from a “strong sell” rating to a “hold” rating in a research report on Friday, October 3rd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

PainReform Price Performance

The company has a market cap of $1.48 million, a P/E ratio of 0.00 and a beta of 0.59. The company has a 50 day moving average of $0.87 and a 200-day moving average of $1.19.

PainReform (NASDAQ:PRFX) last announced its earnings results on Wednesday, October 1st. The company reported ($0.55) earnings per share for the quarter.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.